IMPERIAL II

Imperial College of Science, London, United Kingdom

Group Description

Brief description of legal entity
Imperial College London has well established laboratories at the Hammersmith Hospital Campus for carrying out molecular imaging research in humans and animals along with programmes in genomics, proteomics, and immunology. The Imperial Clinical Imaging Facility and Neuroimaging Unit, Hammersmith Hospital campus houses working groups dealing with PET instrumentation physics, image coregistration, radiochemistry, and neurodegenerative diseases. Imanova houses two Siemens Biograph PET-CT cameras and two 3 tesla Siemens MRIs. Imperial College also has large and small animal PET facilities on the Hammersmith campus and its NMR unit houses 3T human and a 7T animal MRIs (Phillips). The Hammersmith Group, therefore, has all infrastructures necessary to carry out innovative research integrating PET, MRI, and molecular medicine.
Neuroscience research at Imperial College London targets three main themes: neurodegenerative disorders, neuroinflammation, and stroke recovery and is intended to be translational in nature. The Centre for Neuroscience within the Division of Experimental Medicine, Dept of Medicine, ICL, runs disease orientated clinics and provides deep brain stimulation and neuropathology for correlation of PET data with histological findings. It has a close collaboration with the Neurorestoration Programme at Lund University and has held an EC Biomed 5 Shared Cost Grant – “Microglial activation in neurodegeneration in Alzheimer’s disease: A therapeutic target?” (£102,090 to this site) Jan 2000 – Dec 2002 and an EC Biomed2 Shared Cost Grant - BMH4-CT95-0341 “Development of a cell transplantation therapy for patients with Parkinson’s Disease” (450,000 ECU) Jan 1996 - June 1999. It was a member of the EU FP6 DiMI network 2005-2010.

Main tasks
1. To validate a novel PET marker of microglial activation, GE-180, in a head to head comparison with [11C]PK11195 PET in Alzheimer patients.
2. To PET scan MCI patients with imaging biomarkers of amyloid load and microglial activation at baseline and after therapy with an immunomodulator

Participation in INMiND:  WP8 / WP9 (month 1-24)

Previous experience relevant to INMiND tasks

We have reported [11C]PK11195 and [11C]PIB PET scan findings in both Alzheimer and MCI patients. We were also a PET centre in the recent bapineuzimab trial in Alzheimer‟s disease and performed the central PET analysis.


Imperial College London
Prof David BROOKS
INMiND Office
European Institute for Molecular Imaging (EIMI) Waldeyerstr. 15
· 48149 Münster
Tel: +49 251 83 49300 · Fax: +49 251 83 49313
E-Mail: